Compare Illumina, Inc. (ILMN) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Neurocrine Biosciences Inc — how do they compare? Illumina, Inc. trades at $264.24 (market cap $40.43B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B). The key difference: Illumina, Inc. is far larger — about 2.8× Neurocrine Biosciences Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Neurocrine Biosciences Inc for 23 Days on average.
| ILMN | NBIX | |
|---|---|---|
Market Cap | $40.43B | $14.60B |
Volume | 2,948,626 | 1,075,694 |
Sector | Health | Health |
52-Week High | $293.69 | $185.50 |
52-Week Low | $91.00 | $123.10 |
Typical Hold Time | 83 Days | 23 Days |
Enterprise Value | $41.79B | $14.61B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $264.40, down 3.34% on the day but up significantly year-to-date with strong technical momentum. The stock shows bullish moving average signals and trades near pivot point resistance at $268. Fundamentally, the company has delivered three consecutive quarterly earnings beats and returned to profitability in 2025 with $850 million net income after previous losses. Recent catalysts include S&P 500 inclusion effective September 21, 2026, and growing AI integration in genomics applications.
The outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI-driven biological data expansion, while risks involve China market headwinds and elevated valuation multiples. Earnings growth and S&P 500 inclusion provide near-term catalysts, but the stock trades at premium valuations with P/E of 49.96 requiring sustained execution.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
